Previous 10 | Next 10 |
A committee of the European Medicines Agency ( EMA ) recommended the approval of AstraZeneca ( NASDAQ: AZN ) and Sanofi's ( NASDAQ: SNY ) antibody Beyfortus in EU to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in new...
A committee of the European Medicines Agency (EMA) recommended the approval of expanded use of AstraZeneca's ( NASDAQ: AZN ) Evusheld to treat people aged 12 years and older with COVID‑19 who do not require supplemental oxygen and who are at increased risk of progre...
Credit Suisse downgraded AstraZeneca ( NASDAQ: AZN ) to Neutral from Outperform Thursday, arguing that the company shares, following a strong YTD performance, already reflect the company’s potential in oncology. The analyst Dominic Lunn and the team note that AZN ...
Up The Antibodies is a first-of-its-kind educational campaign to support the immunocompromised community and raise awareness of their options to prevent COVID-19, including a long-acting monoclonal antibody Today, AstraZeneca (Nasdaq: AZN) launched Up The A...
Summary Cullinan Oncology's total cash and short-term investment is $611 million, up 94% from the previous quarter. The company's portfolio consists of eight product candidates that can significantly improve the quality of life of patients suffering from various types of cancer. ...
HIMALAYA Phase III trial exploratory results support the benefit of tremelimumab added to IMFINZI in unresectable liver cancer regardless of etiology Updated results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), in ...
AstraZeneca ( NASDAQ: AZN ) and Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) said their drug Enhertu showed clinically meaningful tumor responses in previously-treated patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung...
AstraZeneca ( NASDAQ: AZN ) said ~4 years of follow-up data from a phase 3 trial suggested that a limited five cycles of tremelimumab added to Imfinzi (durvalumab) plus four cycles of chemotherapy improved overall survival (OS) by 25% compared to chemotherapy ...
AstraZeneca ( NASDAQ: AZN ) said Imfinzi, in combination with standard-of-care chemotherapy, showed a clinically meaningful and durable overall survival (OS) benefit for patients with advanced biliary tract cancer (BTC) in a phase 3 trial called TOPAZ-1. As per upda...
DESTINY-Lung02 Phase II trial shows clinically meaningful efficacy and favorable safety at 5.4mg/kg vs. 6.4mg/kg dose of AstraZeneca and Daiichi Sankyo’s ENHERTU in HER2-mutant disease Updated results from DESTINY-Lung01 Phase II trial demonstrate continued durabl...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC Company Name:
AZN Stock Symbol:
NYSE Market:
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NA...
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery AstraZeneca: Revenue and EPS summary Financial performance for Q1 2024 (Growth numbers at CER) Total Revenue up 19% to $12,679m, driven by an 18% increase in Product Sal...